5-(Bromomethyl)pyrimidine-2-carbonitrile | 2209893-51-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-(Bromomethyl)pyrimidine-2-carbonitrile
• CAS: 2209893-51-4
• 化学式: C₆H₄BrN₃
• 分子量: 198.02
• InChiKey: IUACZWUXZJEVFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  49.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds
  申请人：Auspex Pharmaceuticals, Inc.

  公开号：US20180079742A1

  公开（公告）日：2018-03-22

  Described are deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds of structural Formula (I), which are agonists of 5-hydroxytryptamine receptors. Also described are pharmaceutical compositions comprising the deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds, and methods of use thereof.

  描述了结构式(I)的氘代吡啶和嘧啶-2-基甲胺化合物，它们是5-羟色胺受体的激动剂。还描述了包括氘代吡啶和嘧啶-2-基甲胺化合物的药物组合物，以及其使用方法。
• Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
  申请人：Auspex Pharmaceuticals, Inc.

  公开号：US10626105B2

  公开（公告）日：2020-04-21

  Described are deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds of structural Formula (I), which are agonists of 5-hydroxytryptamine receptors. Also described are pharmaceutical compositions comprising the deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds, and methods of use thereof.

  描述了结构式（I）的氘代吡啶-和嘧啶-2-基-甲胺化合物，它们是 5-羟色胺受体的激动剂。还描述了包含氘代吡啶和嘧啶-2-基甲胺化合物的药物组合物及其使用方法。
• [EN] DEUTERIUM-SUBSTITUTED PYRIDIN- AND PYRIMIDIN-2-YL-METHYLAMINE COMPOUNDS<br/>[FR] COMPOSÉS DE PYRIDIN- ET PYRIMIDIN-2-YL-MÉTHYLAMINE SUBSTITUÉS PAR DU DEUTÉRIUM
  申请人：AUSPEX PHARMACEUTICALS INC

  公开号：WO2018057576A1

  公开（公告）日：2018-03-29

  Described are deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds of structural Formula I, which are agonists of 5-hydroxytryptamine receptors. Also described are pharmaceutical compositions comprising the deuterium-substituted pyridin- and pyrimidin-2-yl-methyiamine compounds, and methods of use thereof. Formula (I) In formula (I) X is N or C-R21; R1-R21 a re- independently, hydrogen or deuterium; at least one of R1-R21is deuterium; and at least one of R1-R21 has deuterium enrichment of at least about 1%.